Teleconsent: Enabling informed consent for remote care and research

远程同意：为远程护理和研究提供知情同意

• 批准号: 10654869
• 负责人: Brandon M Welch
• 金额: $ 86.8万
• 依托单位: DOXY.ME, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10654869
• 关键词: Academia; Agreement; COVID-19 pandemic; Caring; Clinical; Clinical Research; Coercion; Collaborations; Communication; Comprehension; Computer software; Confusion; Consent; Consent Forms; Development; Engineering; Equipoise; Ethics; Feedback; Goals; Grant; Health; Health Personnel; Healthcare; Hybrids; Individual; Industry; Informed Consent; Legal; Licensing; Measures; Medical; Methods; Outcome; Participant; Patients; Performance; Persons; Phase; Process; Provider; Research; Research Personnel; Respondent; Risk; Security; Services; Small Business Technology Transfer Research; South Carolina; Telemedicine; Testing; Time; Travel; Universities; Volition; Work; base; cost; decision research; design; experience; handheld mobile device; improved; innovation; novel; preference; pressure; programs; prospective; prototype; recruit; remote consent; remote health care; response; sociodemographics; success; teleconsent; undue influence; usability; virtual consent

PROJECT SUMMARY . Informed consent is legal and ethical requirement in health care and research that assures that individuals have the autonomy to make informed care and research decisions at their own volition, under no coercion or undue influence, and with reasonable understanding of the risks, benefits, and responsibilities of their decisions as they would in-person. Obtaining informed consent is a required yet challenging requirement that can impede participation in health care and clinical research. As a result of the COVID-19 pandemic, telemedicine has proven to be an effective way to deliver health and research services to patients remotely. Yet, providers and researchers (“consenters”) are still required to obtain and document informed consent from patients and research participants (“consentees”). Conventional informed consent approaches are not compatible with telemedicine presenting logistical, technical and security barriers such as travel and cost burdens, low comprehension, confusion and dissatisfaction, alterations in clinical workflows, compliance challenges, and concern over clinical equipoise. Teleconsent is an innovative and proven solution for obtaining remote informed consent developed by Doxy.me, Inc and Medical University of South Carolina. Teleconsent allows consenters to (1) meet and discuss the informed consent by video with consentees over a telemedicine platform, (2) share and collaboratively complete the consent document in real-time, and (3) generate electronically signed copies of the consent for immediate download by both parties. Our Phase I STTR research identified enhancements such as an improved mobile interface, interface for consenters to build and manage consent forms, and the ability for consentees to read consent forms in advance. Optimizing teleconsent to meet the demands of its users is critical, especially during these unprecedented times of the COVID-19 pandemic when most individuals engage in remote care and research. The objective of this Phase II proposal is to refine and expand teleconsent features and deploy them on a large-scale via doxy.me. To achieve this objective, we will refine prototype teleconsent enhancements via iterative user experience assets design and evaluate them employing formal usability methods (Aim 1); build an enhanced, scalable teleconsent interface using Large-Scale Scrum principles and test the new teleconsent features via a formal user acceptance testing program (Aim 2); and implement teleconsent at a large scale with doxy.me providers and researchers to determine performance and measure impact using quantitative metrics for success (Aim 3). Achieving these aims to expand teleconsent features and conduct a large-scale implementation will increase the capacity of consenters to improve the efficiency of the remote informed consent, which will improve recruitment, simplify consent workflows, and enhance telemedicine engagement.

项目摘要。 知情同意是医疗保健和研究中的法律的和伦理要求，它确保个人 有自主权，使知情的护理和研究决定，在自己的意志，没有胁迫或 不适当的影响，并合理理解其风险，利益和责任， 就像他们在人。获得知情同意是一项必要但具有挑战性的要求， 可能会阻碍参与医疗保健和临床研究。由于COVID-19疫情， 远程医疗已被证明是远程向患者提供保健和研究服务的一种有效方式。 然而，提供者和研究人员（“同意者”）仍然需要获得并记录知情同意 患者和研究参与者（“同意者”）。传统的知情同意方法不是 与存在后勤、技术和安全障碍（如旅行和费用）的远程医疗兼容 负担、理解力差、困惑和不满、临床工作流程改变、依从性 挑战和对临床平衡的担忧。EQUIPONSENT是一种创新且经过验证的解决方案， 获得由Doxy.me，Inc和南卡罗来纳州医科大学开发的远程知情同意。 知情同意允许同意者（1）通过视频与同意者会面并讨论知情同意， 远程医疗平台，（2）实时共享和协作完成同意文件，以及（3） 生成同意书的电子签名副本，供双方立即下载。我们的第一阶段 STTR研究确定了改进措施，例如改进的移动的界面，同意者界面， 构建和管理同意书，以及同意者提前阅读同意书的能力。优化 满足其用户的需求是至关重要的，特别是在这些前所未有的时代， COVID-19大流行时，大多数人从事远程护理和研究。该阶段的目的 II的建议是完善和扩展远程发送功能，并通过doxy.me大规模部署这些功能。 为了实现这一目标，我们将通过迭代的用户体验资产来完善原型远程发送增强功能 使用正式的可用性方法设计和评估它们（目标1）;建立一个增强的，可扩展的 远程发送接口，并通过正式的测试， 用户验收测试计划（目标2）;与doxy.me提供商大规模实施远程发送 和研究人员，以确定性能和衡量影响使用定量指标的成功（目的 3）。实现这些目标，扩大远程发送的特点，并进行大规模的实施，将 提高同意者的能力，以提高远程知情同意的效率，这将 改善招募，简化同意流程，并加强远程医疗参与。